0120G0 — Samyang Biopharm Balance Sheet
0.000.00%
Last trade - 00:00- KR₩533bn
- KR₩612bn
- KR₩29bn
Annual balance sheet for Samyang Biopharm, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2025 December 31st | |
|---|---|
| Period Length: | — |
| Source: | Annual Audited Accounts |
| Standards: | IFRS |
| Status: | Final |
| Cash and Equivalents | |
| Short Term Investments | |
| Cash and Short Term Investments | 97,684 |
| Net Total Accounts Receivable | |
| Net Total Receivables | 27,926 |
| Total Inventory | |
| Prepaid Expenses | |
| Total Other Current Assets | |
| Total Current Assets | 170,934 |
| Gross Property, Plant And Equipment | |
| Accumulated Depreciation | |
| Net Property, Plant And Equipment | 146,200 |
| Net Intangible Assets | |
| Long Term Investments | |
| Long Term Notes Receivable | |
| Other Long Term Assets | |
| Total Assets | 339,283 |
| Accounts Payable | |
| Accrued Expenses | |
| Notes Payable / Short Term Debt | |
| Current Portion of Long Term Debt / Capital Leases | |
| Total Other Current Liabilities | |
| Total Current Liabilities | 101,532 |
| Capital Lease Obligations | |
| Total Long Term Debt | |
| Total Debt | |
| Total Other Liabilities | |
| Total Funded Status | |
| Total Liabilities | 104,549 |
| Common Stock | |
| Additional Paid In Capital | |
| Retained Earnings (Accumulated Deficit) | |
| Treasury Stock | |
| Total Equity | 234,734 |
| Total Liabilities & Shareholders' Equity | 339,283 |
| Total Common Shares Outstanding |